Abstract / Description of output
In this issue of Blood, Vaughan et al demonstrate that certain antibodies that are used therapeutically in lymphoma treatment (e.g., rituximab) undergo Fcg receptor IIb (FcgRIIb)–mediated internalization from the B-cell surface in a manner that is independent of activation of FcgRIIb with important implications for the design of antibody-based therapeutics (see figure).
Original language | English |
---|---|
Pages (from-to) | 606-7 |
Number of pages | 2 |
Journal | Blood |
Volume | 123 |
Issue number | 5 |
DOIs |
|
Publication status | Published - 30 Jan 2014 |
Keywords / Materials (for Non-textual outputs)
- Antibodies, Monoclonal
- Humans
- Receptors, IgG